Risk of Nodal Metastases at Laparoscopic Pelvic Lymphadenectomy Using PSA,Gleason Score,and Clinical Stage in Men with Localized Prostate Cancer

Abstract

Laparoscopic pelvic lymph node dissection (LPLND) is a low-morbidity procedure used to stage prostate cancer accurately prior to definitive local therapy. To better select patients for LPLND, we reviewed the clinical features of 120 patients with clinically localized prostate cancer who underwent LPLND to define significant risk factors for nodal metastases. The age ranged from 43 to 79 years (mean 68). Serum prostate specific antigen (PSA) concentration ranged from 1.3 to 329 ng/mL, Gleason score ranged from 2 to 9, and clinical stage ranged from Tib to T3c. Nodal metastases were discovered in 15 patients (13%). Among men with a Gleason score ≥7, 21% had nodal metastases (P = 0.004). A serum PSA >20 ng/mL and clinical stage Tib, T2b, or greater also were statistically significant predictors of lymph node metastases (20% and 19%, respectively). In multivariate analysis, Gleason score significantly predicted nodal metastases when controlling for all other clinical measures. Therefore, LPLND is indicated for any patient with a Gleason score ≥7, PSA >20 ng/mL, and advanced clinical T stage, independently or in combination.